Utilization of model-based meta-analysis to delineate the net efficacy of taspoglutide from the response of placebo in clinical trials

被引:2
作者
Li, Han Qing [1 ]
Xu, Jia Yin [2 ]
Jin, Liang [1 ]
Xin, Ji Le [1 ]
机构
[1] Int Mongolian Hosp Inner Mongolia, State Clin Trial Inst New Drugs, Hohhot 010065, Inner Mongolia, Peoples R China
[2] Int Mongolian Hosp Inner Mongolia, Mongolian Pharmaceut Preparat Ctr, Hohhot 010065, Inner Mongolia, Peoples R China
关键词
PPG; HbA1c; Taspoglutide; Glucagon-like peptide-1; Pharmacodynamics; Meta-analysis; GLUCAGON-LIKE PEPTIDE-1; DOUBLE-BLIND; POPULATION PHARMACOKINETICS; DIABETIC-PATIENTS; GLYCEMIC CONTROL; BODY-WEIGHT; TYPE-2; METFORMIN; ANALOG; PIOGLITAZONE;
D O I
10.1016/j.jsps.2014.11.008
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The objective of this study was to develop quantitative models to delineate the net efficacy of taspoglutide on fasting plasma glucose (FPG) and glycosylated hemoglobin (HbA1c) from the response of placebo in type 2 diabetes patients, and further find pharmacodynamic potency of taspoglutide and FPG for half of maximum reduction responses of FPG and HbA1c, respectively. Several PD data about taspoglutide treatments for type 2 diabetes patients were digitalized from the published papers related with the clinical development of taspoglutide. The model based meta-analysis (MBMA) studies for FPG and HbA1c were performed with Monolix 4.2 software. The MBMA successfully described the effects of placebo and taspoglutide on pharmacological indexes of FPG and HbA1c through mono and multiple combination therapies in clinical trials. The pharmacodynamic potency (25.3 pmo1/1) produced 50% of maximum responses of FPG (-2.39 mmo1/1) from the responses of placebo for FPG (-0.371 mmo1/1); the response change of FPG (-1.81 mmo1/1) affected 50% of maximum response change (-1.74%) for HbA1c from the response of placebo (-0.253%). The leveraging prior knowledge from the longitudinal MBMA will be utilized to guide clinical development of taspoglutide and further support study designs including optimization of dose and duration of therapy. (C) 2014 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University.
引用
收藏
页码:241 / 249
页数:9
相关论文
共 28 条
  • [1] Longitudinal aggregate data model-based meta-analysis with NONMEM: approaches to handling within treatment arm correlation
    Ahn, Jae Eun
    French, Jonathan L.
    [J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2010, 37 (02) : 179 - 201
  • [2] Efficacy and safety of taspoglutide versus sitagliptin for type 2 diabetes mellitus (T-Emerge 4 Trial)
    Richard M. Bergenstal
    Adriana Forti
    Jean-Louis Chiasson
    Michael Woloschak
    Mark Boldrin
    Raffaella Balena
    [J]. Diabetes Therapy, 2012, 3 (1) : 1 - 19
  • [3] Population pharmacokinetics of clindamycin orally and intravenously administered in patients with osteomyelitis
    Bouazza, Naim
    Pestre, Vincent
    Jullien, Vincent
    Curis, Emmanuel
    Urien, Saik
    Salmon, Dominique
    Treluyer, Jean-Marc
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 74 (06) : 971 - 977
  • [4] Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide
    Brendel, Karl
    Comets, Emmanuelle
    Laffont, Celine
    Laveille, Christian
    Mentre, France
    [J]. PHARMACEUTICAL RESEARCH, 2006, 23 (09) : 2036 - 2049
  • [5] A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying type 2 diabetes mellitus
    de Winter, Willem
    DeJongh, Joost
    Post, Teun
    Ploeger, Bart
    Urquhart, Richard
    Moules, Ian
    Eckland, David
    Danhof, Meindert
    [J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2006, 33 (03) : 313 - 343
  • [6] Discovery and characterization of taspoglutide, a novel analogue of human glucagon-like peptide-1, engineered for sustained therapeutic activity in type 2 diabetes
    Dong, J. Z.
    Shen, Y.
    Zhang, J.
    Tsomaia, N.
    Mierke, D. F.
    Taylor, J. E.
    [J]. DIABETES OBESITY & METABOLISM, 2011, 13 (01) : 19 - 25
  • [7] Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes - Preclinical biology and mechanisms of action
    Drucker, Daniel J.
    [J]. DIABETES CARE, 2007, 30 (06) : 1335 - 1343
  • [8] Pharmacokinetic and Pharmacodynamic Modeling of Exendin-4 in Type 2 Diabetic Goto-Kakizaki Rats
    Gao, Wei
    Jusko, William J.
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2011, 336 (03) : 881 - 890
  • [9] Gavin JR, 2010, J AM OSTEOPATH ASSOC, V110, pS2
  • [10] Quantitative Model of the Relationship Between Dipeptidyl Peptidase-4 (DPP-4) Inhibition and Response: Meta-Analysis of Alogliptin, Saxagliptin, Sitagliptin, and Vildagliptin Efficacy Results
    Gibbs, John P.
    Fredrickson, Jill
    Barbee, Todd
    Correa, Itzela
    Smith, Brian
    Lin, Shao-Lee
    Gibbs, Megan A.
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 52 (10) : 1494 - 1505